

SAFETY DATA SHEET

Revision date: 16-May-2014

Version: 2.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier

Material Name: Ibutilide Fumarate Injection

Trade Name:Corvert InjectionChemical Family:Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product used as cardiovascular drug

Details of the Supplier of the Safety Data Sheet Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Other Hazards
Australian Hazard Classification
(NOHSC):No data available
Non-Hazardous Substance. Non-Dangerous Goods.Note:This document has been prepared in accordance with standards for workplace safety, which
requires the inclusion of all known hazards of the product or its ingredients regardless of the
potential risk. The precautionary statements and warning included may not apply in all cases.
Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<u>Hazardous</u>

Ingredient	CAS Number	EU	EU Classification	GHS	%
_		EINECS/ELINCS		Classification	
		List			

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

SAFETY DATA SHEET

Material Name: Ibutilide Fumarate Injection Revision date: 16-May-2014

3. COMPOSITION / INFORMATION ON INGREDIENTS					
Ibutilide Fumarate	122647-32-9	Not Listed	Repr. Cat.2,R61;	Repr. 1B,H360D;	0.01
			Xi,R36	Eye Irrit. 2A,H319	

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sodium acetate trihydrate	6131-90-4	Not Listed	Not Listed	Not Listed	*
Sodium chloride	7647-14-5	231-598-3	Not Listed	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information:

* Proprietary

_.

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES	 	

.

Description of First Aid Measures

Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Most Important Symptoms and Effe	ects, Both Acute and Delayed
Symptoms and Effects of Exposure: Medical Conditions Aggravated by Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. None known
Indication of the Immediate Medica	I Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous CombustionFormation of toxic gases is possible during heating or fire.Products:

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Material Name: Ibutilide Fumarate Injection Revision date: 16-May-2014

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containme Measures for Cleaning / Collecting:	nt and Cleaning Up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store as directed by product packaging.
Specific end use(s):	Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium chloride Latvia OEL - TWA Lithuania OEL - TWA	5 mg/m ³ 5 mg/m ³
Ibutilide Fumarate Pfizer OEL TWA-8 Hr:	5µg/m³
Exposure Controls Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

Material Name: Ibutilide Fumarate Injection Revision date: 16-May-2014 Page 4 of 8 Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Odor: Molecular Formula:	Liquid No data available. Mixture	Color: Odor Threshold: Molecular Weight:	Colorless No data available. Mixture
Solvent Solubility: Water Solubility: Solubility: pH: Melting/Freezing Point (°C): Boiling Point (°C): Partition Coefficient: (Method, pH, E Sodium acetate trihydrate No data available Sodium chloride No data available Ibutilide Fumarate No data available Decomposition Temperature (°C):	No data available No data available Soluble: Water No data available. No data available No data available. ndpoint, Value)		
Evaporation Rate (Gram/s): Vapor Pressure (kPa): Vapor Density (g/ml): Relative Density: Viscosity: Flammablity:	No data available No data available No data available No data available No data available		
Autoignition Temperature (Solid) (°C): Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.):		No data available No data available No data available No data available No data available	

10. STABILITY AND REACTIVITY

Reactivity: Chemical Stability:	No data available Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition	No data available
Products:	

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects	
General Information:	The information included in this section describes the potential hazards of the individual
Long Term:	ingredients. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system, the developing fetus.

SAFETY DATA SHEET

Material Name: Ibutilide Fumarate Injection Revision date: 16-May-2014 Page 5 of 8 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Known Clinical Effects:

Convulsions possible at high overdosage. Clinical use of this drug has caused headache, nausea, vomiting, changes in heart rate, impaired heart conduction (atrioventricular block), changes in blood pressure.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Ibutilide Fumarate

 Rat
 Oral
 LD 50
 > 500 mg/kg

 Rat
 Para-periosteal
 LD 50
 50mg/kg

 Acute Toxicity Comments:
 A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Ibutilide Fumarate

Eye Irritation Rabbit Severe Skin Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ibutilide Fumarate

14 Day(s) Rat Intravenous 12.5 mg/kg LOAEL Central nervous system 14 Day(s) Dog Intravenous < 2.5 mg/kg/day NOAEL 90 Day(s) Rat Oral 4 mg/kg/day NOAEL Liver, Gastrointestinal system 90 Day(s) Dog Oral 4 mg/kg/day NOEL Central Nervous System, Male reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ibutilide Fumarate

Reproductive & Fertility Rat Oral 5 mg/kg/day NOAEL Developmental toxicity **Reproductive & Fertility** Rat Oral 5 mg/kg/day NOAEL Maternal Toxicity Reproductive & Fertility Rat Oral 5 mg/kg/day NOAEL Paternal toxicity Embryo / Fetal Development Rat Oral 5 mg/kg/day NOAEL Not Teratogenic Oral Embryo / Fetal Development Rabbit 20 mg/kg/day LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ibutilide Fumarate

Bacterial Mutagenicity (Ames)SalmonellaNegativeUnscheduled DNA SynthesisNegativeIn Vitro MicronucleusNegativeMammalian Cell MutagenicityMouse LymphomaNegative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11. TOXICOLOGICAL INFORMATION

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State
specific and Community specific provisions must be considered. Considering the relevant
known environmental and human health hazards of the material, review and implement
appropriate technical and procedural waste water and waste disposal measures to prevent
occupational exposure and environmental release. It is recommended that waste minimization
be practiced. The best available technology should be utilized to prevent environmental
releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: None required This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Material Name: Ibutilide Fumarate Injection Revision date: 16-May-2014

15. REGULATORY INFORMATION

Sodium acetate trihydrate CERCLA/SARA 313 Emission reporting California Proposition 65 Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Not Listed
Sodium chloride	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present 231-598-3
Water for Injection	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): REACH - Annex IV - Exemptions from the obligations of Register: EU EINECS/ELINCS List	Not Listed Not Listed Present Present Present 231-791-2
Ibutilide Fumarate CERCLA/SARA 313 Emission reporting California Proposition 65 EU EINECS/ELINCS List	Not Listed Not Listed Not Listed

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation

Toxic to Reproduction: Category 2 Xi - Irritant R36 - Irritating to eyes. R61 - May cause harm to the unborn child. Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information. **Reasons for Revision:** Updated Section 3 - Composition / Information on Ingredients. Updated Section 2 - Hazard Identification. Updated Section 6 - Accidental Release Measures. Updated Section 8 -Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory Information. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 16 - Other Information. Updated Section 10 - Stability and Reactivity. 16-May-2014 **Revision date:** Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations Prepared by:

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet